Cholesterol-lowering drugs may not prevent Alzheimer's disease

Jan 16, 2008

Contrary to some reports, taking statins, which are cholesterol-lowering drugs, offers no protection against Alzheimer’s disease, according to research published in the January 16, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology.

The study involved 929 Catholic clergy members who were an average of 75 years old, free of dementia at the beginning of the study and enrolled in the Religious Orders Study, an ongoing study of aging and Alzheimer’s disease. All of the participants agreed to a brain autopsy at the time of their death and underwent annual cognitive tests for up to 12 years.

At the beginning of the study, 119 people were taking a statin. During the 12-year follow-up period, 191 people developed Alzheimer’s disease, of whom 16 used statins at the start of the study.

“Some studies have suggested people taking cholesterol-lowering drugs are less likely to have Alzheimer’s disease, but our longitudinal findings found no relation between statin use and Alzheimer’s,” said study author Zoe Arvanitakis, MD, MS, Associate Professor of the Department of Neurological Sciences at Rush University Medical Center in Chicago and member of the American Academy of Neurology. “The study also found no association between taking statins and a slower cognitive decline among older people.”

In addition, researchers performed brain autopsies on more than 250 people who died during the study to examine the relation of statins to Alzheimer’s disease pathology and stroke in the brain, the two common pathological causes of dementia. The study found statin use at any time during the course of the study had no effect on pathology of Alzheimer’s disease or strokes.

Arvanitakis says the study is limited in that there were relatively few statin users among those who died. She says future studies will need to look at the possibility of associations of statins with other pathologic changes of Alzheimer’s disease not examined in this study.

Source: American Academy of Neurology

Explore further: Bristol-Myers: FDA blocks hepatitis C drug for now

add to favorites email to friend print save as pdf

Related Stories

Statins can protect against Alzheimer's disease

Jun 22, 2009

High cholesterol levels are considered to be a risk factor not only for cardiovascular disease including stroke, but also for the development of Alzheimer's disease. Therefore, many cholesterol lowering drugs, including statins, ...

Compounds fend off Alzheimer's disease amyloid pathology

Sep 08, 2010

A team of scientists, led by University of California, San Diego School of Medicine researchers, has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary ...

Rethinking statins: A wonder drug or 'false hope'?

Aug 11, 2010

As the world's most-prescribed class of medications, statins indisputably qualify for the commercial distinction of "blockbuster." About 24 million Americans take the drugs - marketed under such commercial names as Pravachol, ...

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

13 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

SDMike
not rated yet Jan 17, 2008
Either this abstract or the original report is very poor. Only some statins are claimed to reduce the onset age of dementia. With out reporting the specific statins observed and unless the study used a factor analysis design where the specific statin chemical was a variable, the study tells us nothing. The headline and conclusion is BOGUS.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.